Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid in Asian Patients with Bone Metastases
NCT01920568Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2013
- Primary completion
- Feb 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of denosumab in bone metastasis, sponsored by GSK. Started Aug 2013; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT01920568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01920568.